bannerhome
 
 

Science

 

2021 Oncology R&D Day

2021 Oncology R&D Day

DOWNLOAD
 

Versamune®: A New Generation of Cancer Immunotherapies

White Paper

A Simplified Overview of How the Versamune® Platform Overcomes Key Limitations of Immuno-Oncology

DOWNLOAD

 

 


Wood LV, et al. 2023. HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy. Presented at: European Society for Medical Oncology Targeted Anticancer Therapies; March 6-8, 2023. Paris, France. Abstract: P44.

Toney NJ, Gatti-Mays ME, Tschernia NP, Strauss J, Gulley JL, Schlom J, Donahue RN. Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12. International Immunopharmacology. 2023. 116; 109736. ISSN 1567-5769.

Henson TR, Richards KA, Gandhapudi SK, Woodward JG, Sant AJ. R-DOTAP Cationic Lipid Nanoparticles Outperform Squalene-Based Adjuvant Systems in Elicitation of CD4 T Cells after Recombinant Influenza Hemagglutinin Vaccination. Viruses. 2023; 15(2):538.

 


Gandhapudi SK, Shi H, Ward MR, Bush JP, Avdiushko M, Sundarapandiyan K, Wood LV, Dorrani M, Fatima A, Dervan J, Bedu-Addo F, Conn G, Ross TM, Woodward JG. 2023. Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice. Viruses; 15(2):432.

Klopp A, et al. 2022. IMMUNOCERV, an ongoing Phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers. Presented at: Society for Immunotherapy of Cancer; November 8-12, 2022. Boston, MA. Abstract: 674.

Goswami M, et al. 2022. Immune correlates associated with clinical benefit in patients with checkpoint refractory HPV-associated malignancies treated with triple combination immunotherapy. Presented at: Society for Immunotherapy of Cancer; November 8-12, 2022. Boston, MA. Abstract: 695.

 


Gandhapudi SK, et al. 2022. Development of targeted T-cell cancer immunotherapies based on a novel enantiomeric cationic lipid that promotes antigen cross-presentation and upregulation of type I interferons. Presented at: American Association of Clinical Research Tumor Immunology and Immunotherapy; October 21-24, 2022. Boston, MA. Abstract: B24.

Shi H, et al. 2022. Infectimune™ enhances antibodies elicited by computational optimized broadly reactive antigen (COBRA) hemagglutinin influenza vaccine. Presented at American Society of Virology Annual Meeting. July 16-20, 2022. Madison, WI. Abstract 3733830.

Weiss J, et al. 2022. PDS0101 a novel Type 1 interferon and CD8+ T cell activating immunotherapy in combination with pembrolizumab in subjects with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). Presented at American Society of Clinical Oncology Annual Meeting. June 3-7, 2022. Chicago, IL. Abstract 6041.

 


Strauss J, et al. 2022. Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV16-positive malignancies. Presented at American Society of Clinical Oncology Annual Meeting. June 3-7, 2022. Chicago, IL. Abstract 2518.

Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Presented at: American Society of Clinical Oncology 2021 Annual Meeting; June 4-8, 2021; Virtual. Abstract: 2501.

Sun W, McCroskery s, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schafer A, Dinnon KH III, Innis BL, Garcia-Sastre A, Krammer F, Baric RS, Palese P. 2020. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines. 8(4): 771.

Smalley Rumfield C, Pellom ST, Morillon II YM, Schlom J, Jochems C. 2020. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J. for ImmunoTherapy of Cancer 8:e000612.

Gandhapudi SK, Ward M, Bush JPC, Bedu-Addo F, Conn G, Woodward JG. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536.

Vasievich EA, Ramishetti S, Zhang Y, Huang L. 2012. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol Pharmaceutics. 9(2): 261-268.

Vasievich EA, Chen W, Huang L. 2011. Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer
vaccine. Cancer Immunol Immunother. 60(5): 629-638.

Chen W, Yan W, Huang L. 2008. A simple but effective cancer vaccine consisting of an antigen and a
cationic lipid. Cancer Immunol Immunother. 57(4): 517-530.

Yan W, Chen W, Huang L. 2007. Mechanism of adjuvant activity of
cationic liposome: phosphorylation of a MAP kinase, ERK and induction
of chemokines. Molecular Immunology 44(15): 3672-3681.

Vangasseri DP, Cui Z, Chen W, Hokey DA, Falo LD Jr, Huang L. 2006. Immunostimulation of dendritic cell
by cationic liposomes. Mol Membr Biol. 23(5): 385-395.

Zelphati, O., Y. Wang, S. Kitada, J. C. Reed, P. L. Felgner, and J. Corbeil. 2001. Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem 276: 35103-35110.

Felgner, P. L., T. R. Gadek, M. Holm, R. Roman, H. W. Chan, M. Wenz, J. P. Northrop, G. M. Ringold, and M. Danielsen. 1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 84: 7413-7417.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up

pdf

This website use cookies to facilitate the use of the website, improve its performance and security, personalize the proposed content.